Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
University of Oklahoma
Study ID
NCT03526432
Phase
PHASE2
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    Bevacizumab will be administered by IV infusion at 15mg/kg on Day 1 of every 21-days cycle.
  • Atezolizumab — DRUG
    Atezolizumab will be administered by IV infusion at a fixed dose of 1200 mg on Day 1 of each 21-day cycle until disease progression, unacceptable toxicity, loss of clinical benefit as determined by the investigator.

Study Details

This is a single arm, Phase II study using the combination of atezolizumab and bevicacizumab in women with advanced, recurrent or persistent endometrial cancer. Safety and futility of this drug combination will be assessed to see what effect this treatment has on this patient population.

Key Dates

Start date
Aug 8, 2018
Status verified
Jun 2026
Primary completion
Jun 30, 2026
Completion
Sep 30, 2026

Study Design

Enrollment
110 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Bevacizumab + Atezolizumab

Primary Outcome Measure

Number of patients who experience complete or partial tumor response [ Time Frame: 3 years ]

Locations (3)

FacilityCityStateZIPSite coordinators
UAB Women and Infants CenterBirminghamAlabama35233-
Washington University School of MedicineSt LouisMissouri63108-
Stephenson Cancer Center, University of Oklahoma Health Sciences CenterOklahoma CityOklahoma73117-

Find similar trials in Birmingham, AL

By condition
Endometrial cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
UAB Women and Infants Center· Birmingham, ALWashington University School of Medicine· St Louis, MOStephenson Cancer Center, University of Oklahoma Health Sciences Center· Oklahoma City, OK

Related Studies